Catalent Adds Capacity at Kansas City Clinical Supplies Facility

Article

The second phase of a $5.5-million expansion adds controlled-substance and controlled-temperature storage to Catalent clinical trials facility.

Catalent Pharma Solutions announced on May 17, 2018 the completion of the second phase of a $5.5-million expansion program at its Kansas City, MO facility, which increased the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.

The expansion included a Drug Enforcement Administration Schedule I and II controlled substance vault; 3600-sq.-ft. of additional storage; controlled-temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations; a sampling room; and an emergency generator.

The 450,000-sq.-ft. facility provides development and analytical support through to packaging and distribution, the company reported in a press statement. Previously, the company announced expansions at clinical supply facilities in Philadelphia and Singapore.

Source: Catalent Pharma Solutions

 

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.